Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

Zhen Yuan; Shuyuan Wang; Kemin Ni; Yixiang Zhan; Hong Ma; Xinyu Liu; Ran Xin; Xingyu Zhou; Zhaoce Liu; Xuanzhu Zhao; Xin Yin; Hangyu Ping; Yaohong Liu; Wanting Wang; Suying Yan; Qiurong Han; Wei Cui; Xipeng Zhang; Qinghuai Zhang; Chunze Zhang

doi:10.12659/MSM.937757

19 September 2022 : Clinical Research

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

Zhen Yuan^12ABCDEF, Shuyuan Wang^12ABCDEF, Kemin Ni

^12ACDF, Yixiang Zhan^12ACDF, Hong Ma^1BDF, Xinyu Liu^13ABC, Ran Xin

^2ABC, Xingyu Zhou^2BC, Zhaoce Liu^12BC, Xuanzhu Zhao^14BC, Xin Yin^2BC, Hangyu Ping^2BC, Yaohong Liu^2BC, Wanting Wang^4BC, Suying Yan^4BC, Qiurong Han^4BC, Wei Cui

^5CD, Xipeng Zhang^167ADF, Qinghuai Zhang^167ABCD, Chunze Zhang^167ABCDEFG*

DOI: 10.12659/MSM.937757

Med Sci Monit 2022; 28:e937757

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Supplementary Table 3 Baseline characteristics of the patients who received CAPEOX and FOLFOX before and after propensity matching.

Variables	Postoperative mSEPT9 positive before matching			Longitudinal mSETP9 positive before matching
Variables	CAPEOX (n=20)	FOLFOX (n=30)	p	CAPEOX (n=41)	FOLFOX (n=50)	p

≤60 years	4 (20.0)	12 (40.0)	0.216	11 (26.8)	18 (36.0)	0.376
>60 years	16 (80.0)	18 (60.0)	0.216	30 (73.2)	32 (64.0)	0.376

Female	6 (30.0)	15 (50.0)	0.243	12 (29.3)	18 (36.0)	0.274
Male	14 (70.0)	15 (50.0)	0.243	29 (70.7)	32 (64.0)	0.274

Well/moderate	10 (50.0)	17 (56.7)	0.774	25 (61.0)	27 (54.0)	0.530
Poor	10 (50.0)	13 (43.3)	0.774	16 (39.0)	23 (46.0)	0.530

Adenocarcinoma	17 (85.0)	29 (96.7)	0.289	37 (90.2)	48 (96.0)	0.403
Other types	3 (15.0)	1 (3.3)	0.289	4 (9.8)	2 (4.0)	0.403

II	8 (40.0)	7 (23.3)	0.228	15 (36.6)	15 (30.0)	0.654
III	12 (60.0)	23 (76.7)	0.228	26 (63.4)	35 (70.0)	0.654

pN0	8 (40.0)	7 (23.3)	0.228	15 (36.6)	15 (30.0)	0.654
pN1/2	12 (60.0)	23 (76.7)	0.228	26 (63.4)	35 (70.0)	0.654

pT1/2	1 (5.0)	2 (6.7)	1.000	1 (2.4)	2 (4.0)	1.000
pT3/4	19 (95.0)	28 (93.3)	1.000	40 (97.6)	48 (96.0)	1.000

Rectum	8 (40.0)	16 (53.3)	0.012	19 (46.3)	25 (50.0)	0.051
Left colon	10 (50.0)	4 (13.3)		18 (43.9)	12 (24.0)
Right colon	2 (10.0)	10 (33.3)		4 (9.8)	13 (26.0)

Yes	3 (15.0)	15 (50.0)	0.016	8 (19.5)	28 (56.0)	0.015
No	17 (85.0)	15 (50.0)	0.016	33 (80.5)	22 (44.0)	0.015



≤60 years	4 (30.8)	3 (23.1)	1.000	7 (23.3)	8 (26.7)	1.000
>60 years	9 (69.2)	10 (76.9)	1.000	23 (76.7)	22 (73.3)	1.000

Female	4 (30.8)	5 (38.5)	1.000	9 (30.0)	10 (33.3)	1.000
Male	9 (69.2)	8 (61.5)	1.000	21 (70.0)	20 (66.7)	1.000

Well/moderate	8 (61.5)	7 (53.8)	1.000	18 (60.0)	18 (60.0)	1.000
Poor	5 (38.5)	6 (46.2)	1.000	12 (40.0)	12 (40.0)	1.000

Adenocarcinoma	12 (92.3)	12 (92.3)	1.000	28 (93.3)	28 (93.3)	1.000
Other types	1 (7.7)	1 (7.7)	1.000	2 (6.7)	2 (6.7)	1.000

II	6 (46.2)	4 (30.8)	0.688	12 (40.0)	10 (33.3)	0.789
III	7 (53.8)	9 (69.2)	0.688	18 (60.0)	20 (66.7)	0.789

pN0	6 (46.2)	4 (30.8)	0.688	12 (40)	10 (33.3)	0.789
pN1/2	7 (53.8)	9 (69.2)	0.688	18 (60)	20 (66.7)	0.789

pT1/2	1 (7.7)	0 (0.0)	1.000	1 (3.3)	1 (3.3)	1.000
pT3/4	12 (92.3)	13 (100)	1.000	29 (96.7)	29 (96.7)	1.000

Rectum	4 (30.8)	7 (53.8)	0.119	15 (50.0)	18 (60.0)	0.735
Left colon	7 (53.8)	2 (15.4)		11 (36.7)	9 (30.0)
Right colon	2 (15.4)	4 (30.8)		4 (13.3)	3 (10.0)

Yes	1 (7.7)	6 (46.2)	0.030	4 (13.3)	12 (40.0)	0.039
No	12 (92.3)	7 (53.8)	0.030	26 (86.7)	18 (60.0)	0.039
CRC – colorectal cancer; mSEPT9 – methylated setpin9; ACT – adjuvant chemotherapy.

Back to the Article

Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer

Your Privacy